Page last updated: 2024-10-30

leflunomide and Hearing Loss, Sensorineural

leflunomide has been researched along with Hearing Loss, Sensorineural in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Hearing Loss, Sensorineural: Hearing loss resulting from damage to the COCHLEA and the sensorineural elements which lie internally beyond the oval and round windows. These elements include the AUDITORY NERVE and its connections in the BRAINSTEM.

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Rahman, MU	1
Poe, DS	1
Choi, HK	1

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Pilot Trial of Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss[NCT02828033]	Early Phase 1	10 participants (Anticipated)	Interventional	2017-02-01	Recruiting
Clinical Trial of Etanercept (TNF-α Blocker) for Treatment of Blast-Induced Tinnitus[NCT04066348]	Phase 2	310 participants (Anticipated)	Interventional	2022-07-01	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for leflunomide and Hearing Loss, Sensorineural

Article	Year
Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2001, Volume: 22, Issue:5 Topics: Adult; Aged; Antirheumatic Agents; Cochlear Diseases; Etanercept; Female; Follow-Up Studies; Hearing	2001
Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2001, Volume: 22, Issue:5 Topics: Adult; Aged; Antirheumatic Agents; Cochlear Diseases; Etanercept; Female; Follow-Up Studies; Hearing	2001
Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2001, Volume: 22, Issue:5 Topics: Adult; Aged; Antirheumatic Agents; Cochlear Diseases; Etanercept; Female; Follow-Up Studies; Hearing	2001
Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2001, Volume: 22, Issue:5 Topics: Adult; Aged; Antirheumatic Agents; Cochlear Diseases; Etanercept; Female; Follow-Up Studies; Hearing	2001